Teva Pharma Updates 2023 Revenue Guidance and Maintains Adjusted EPS Forecast

Gelonghui August 2nd丨Teva Pharmaceutical (TEVA.US) raised its revenue forecast for the fiscal year 2023 from $14.8 billion - $15.4 billion to $15.0 billion - $15.4 billion, with an expected revenue of $15.02 billion; maintained the adjusted earnings per share forecast at $2.25 - $2.55, with an expected value of $2.27.